Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Acute hepatitis caused by a natural lipid-lowering product: when "alternative" medicine is no "alternative" at all.

Grieco A, Miele L, Pompili M, Biolato M, Vecchio FM, Grattagliano I, Gasbarrini G.

J Hepatol. 2009 Jun;50(6):1273-7. doi: 10.1016/j.jhep.2009.02.021. Epub 2009 Mar 31. Erratum in: J Hepatol. 2010 Mar;52(3):466.

2.

Defining patient risks from expanded preventive therapies.

Tolman KG.

Am J Cardiol. 2000 Jun 22;85(12A):15E-9E. Review.

PMID:
10858489
3.

Safety of statins: effects on muscle and the liver.

Vasudevan AR, Hamirani YS, Jones PH.

Cleve Clin J Med. 2005 Nov;72(11):990-3, 996-1001. Review.

PMID:
16315438
4.

Elevated hepatic transaminases associated with telithromycin therapy: a case report and literature review.

Bolesta S, Roslund BP.

Am J Health Syst Pharm. 2008 Jan 1;65(1):37-41. Review.

PMID:
18159037
5.

Guggul for hyperlipidemia: a review by the Natural Standard Research Collaboration.

Ulbricht C, Basch E, Szapary P, Hammerness P, Axentsev S, Boon H, Kroll D, Garraway L, Vora M, Woods J; Natural Standard Research Collaboration..

Complement Ther Med. 2005 Dec;13(4):279-90. Epub 2005 Sep 23. Review.

PMID:
16338199
6.

Traditional Chinese lipid-lowering agent red yeast rice results in significant LDL reduction but safety is uncertain - a systematic review and meta-analysis.

Gerards MC, Terlou RJ, Yu H, Koks CH, Gerdes VE.

Atherosclerosis. 2015 Jun;240(2):415-23. doi: 10.1016/j.atherosclerosis.2015.04.004. Epub 2015 Apr 12. Review.

7.

[Biochemical characteristics of toxic hepatitis].

Ishii H, Kato S, Ito D, Tsuchiya M.

Nihon Rinsho. 1985 Jun;43(6):1139-43. Review. Japanese. No abstract available.

PMID:
2864460
8.

Red yeast rice for the treatment of dyslipidemia.

Burke FM.

Curr Atheroscler Rep. 2015 Apr;17(4):495. doi: 10.1007/s11883-015-0495-8. Review.

PMID:
25728312
9.

The role of red yeast rice for the physician.

Gordon RY, Becker DJ.

Curr Atheroscler Rep. 2011 Feb;13(1):73-80. doi: 10.1007/s11883-010-0145-0. Review.

PMID:
21061097
10.

[Hepatic tolerance of atypical antipsychotic drugs].

Dumortier G, Cabaret W, Stamatiadis L, Saba G, Benadhira R, Rocamora JF, Aubriot-Delmas B, Glikman J, Januel D.

Encephale. 2002 Nov-Dec;28(6 Pt 1):542-51. Review. French.

PMID:
12506267
11.

The liver and lovastatin.

Tolman KG.

Am J Cardiol. 2002 Jun 15;89(12):1374-80. Review.

PMID:
12062731
12.

[Behavior of gamma glutamyl transpeptidase in hepatobiliary diseases].

Kresbach E, Thurnher H.

Wien Med Wochenschr. 1973 Apr 21;123(16):253-8. Review. German. No abstract available.

PMID:
4144931
13.

[Autoimmune hepatitis caused by acute hepatitis due to hepatitis A virus].

Muñoz Bertrán E, Rosa Salazar V, Hostalet Robles F, Correa Estañ JA, Belda Abad G, Muñoz Ramírez E.

Gastroenterol Hepatol. 2002 Oct;25(8):501-4. Review. Spanish.

PMID:
12361532
14.

[Impact of lipid lowering therapy on liver function].

Paragh G, Fülöp P.

Orv Hetil. 2009 Jun 28;150(26):1205-12. doi: 10.1556/OH.2009.28629. Review. Hungarian.

PMID:
19546077
15.

Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.

Eslami L, Merat S, Malekzadeh R, Nasseri-Moghaddam S, Aramin H.

Cochrane Database Syst Rev. 2013 Dec 27;(12):CD008623. doi: 10.1002/14651858.CD008623.pub2. Review.

PMID:
24374462
16.

Can "statins" be used in patients with hepatitis B?

Safeer RS.

Postgrad Med. 2002 May;111(5):119-20. Review. No abstract available.

PMID:
12040858
17.

Efficacy and long-term adverse effect pattern of lovastatin.

Tobert JA.

Am J Cardiol. 1988 Nov 11;62(15):28J-34J. Review.

PMID:
3055921
18.

Lipid-lowering agents and hepatotoxicity.

Demyen M, Alkhalloufi K, Pyrsopoulos NT.

Clin Liver Dis. 2013 Nov;17(4):699-714, x. doi: 10.1016/j.cld.2013.07.016. Review.

PMID:
24099026

Supplemental Content

Support Center